[Effect of beta-ionone in human mammary cancer cells (Er-) by MAPK pathway].
OBJECTIVE
To investigate the effect of cell proliferation in human breast cancer cells (MDA-MB 435), which has non-receptor of estrogen (Er), induced by beta-ionone. MDA-MB 435 cells were treated with different beta-ionone concentrations (25, 50, 100 and 200 micromol/L), with a negative control.


METHODS
Such as curve of cell growth, cellular mitosis, the clone formatting, DNA synthesis, and western blotting for protein of PCNA and MAPK pathway were employed.


RESULTS
beta-ionone inhibited the cell proliferation, cellular mitosis, clone formatting and DNA synthesis and reduced expression of PCNA protein in MDA-MB 435 cells. The inhibitory frequency (IF) showed a dose-dependent responses as the concentrations of beta-ionone increased. Seven days after treatment with various concentrations of beta-ionone, as mentioned above, the inhibition rates were 45.65%, 71.24%, 81.53%, and 84.93%, respectively. Its IC50 value was 42.0 micromol/L for MDA-MB 435 cells. The IF from cellular mitosis of MDA-MB 435 cells treated by beta-ionone were - 34.57%-58.857% at 24 h and - 30.05%-75.12% at 48 h, from the clone formatting assay, - 4.44%-63.79% at 24 h and 6.42%-95.55% at 48 h, from DNA synthesis, 17.00%-57.56% at 24h and 62.25%-78.35% at 48 h. The further study was found that beta-ionone inhibited the expression of PCNA which to be related to cell cycle and reduced ERK, MEK-1 proteins expression and promoted the expression of JNK and MKP-1 proteins related to MAPK pathway in MDA-MB 435 cells.


CONCLUSIONS
beta-ionone could inhibit MDA-MB 435 cells proliferation by regulating MAPKs pathway. It may be one of the effects of beta-ionone in anticancer.
Liu
Jia-ren
JR
College of Public Health, Harbin Medical University, Harbin 150086, China.
Yang
Yan-mei
YM
Dong
Hong-wei
HW
Sun
Xiang-rong
XR
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000378:metabolism; D048055:Mitogen-Activated Protein Kinase 8 / Q000378:metabolism; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism*; D045792:Norisoprenoids / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000378:metabolism*
D000970:Antineoplastic Agents; D045792:Norisoprenoids; D011960:Receptors, Estrogen; C008157:beta-ionone; D048055:Mitogen-Activated Protein Kinase 8; D048369:MAP Kinase Kinase 1; C482125:MAP2K1 protein, human; D020929:Mitogen-Activated Protein Kinase Kinases